Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

被引：22

作者：

Qualls, David A.

Lambert, Nicholas ^{[1
,2
]}

Caimi, Paolo F. ^{[3
]}

Merrill, Mwanasha ^{[4
]}

Pullarkat, Priyanka ^{[5
]}

Godby, Richard C. ^{[6
]}

Bond, David A. ^{[6
]}

Wehmeyer, Graham T. ^{[9
,10
]}

Romancik, Jason ^{[11
]}

Amoozgar, Behzad ^{[12
]}

Leslie, Lori ^{[11
]}

Nastoupil, Loretta J. ^{[1
,13
,14
]}

Crombie, Jennifer L. ^{[4
]}

Abramson, Jeremy S. ^{[4
]}

Khurana, Arushi ^{[6
]}

Nowakowski, Grzegorz S. ^{[5
]}

Maddocks, Kami ^{[7
,8
]}

Rutherford, Sarah C. ^{[9
,10
]}

Kahl, Brad ^{[12
]}

Okwali, Michelle ^{[1
]}

Buege, Michael J. ^{[1
]}

Seshan, Venkatraman ^{[1
]}

Batlevi, Connie L. ^{[1
]}

Salles, Gilles ^{[1
,15
,16
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, Div Hematol Malignancies, New York, NY 10065 USA

[2] Baylor Coll Med, Dept Med, Houston, TX USA

[3] Cleveland Clin Fdn, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH USA

[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[5] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA USA

[6] Mayo Clin, Div Hematol & Oncol, Dept Internal Med, Rochester, MN USA

[7] Ohio State Univ, James Canc Hosp, Columbus, OH USA

[8] Ohio State Univ, Solove Res Inst, Columbus, OH USA

[9] Weill Cornell Med, Dept Med, Meyer Canc Ctr, New York, NY USA

[10] New York Presbyterian Hosp, New York, NY USA

[11] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA

[12] Washington Univ, Sch Med, Dept Med, St Louis, MO USA

[13] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Lymphoma Div, Hackensack, NJ USA

[14] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[15] Weill Cornell Med Coll, New York, NY 10065 USA

[16] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA

来源：

BLOOD | 2023年 / 142卷 / 26期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1182/blood.2023021274

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL. © 2023 The American Society of Hematology

引用

页码：2327 / 2331

页数：5

共 50 条

[1] Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study
Qualls, David
Buege, Michael J.
Dao, Phuong
Caimi, Paolo F.
Rutherford, Sarah C.
Wehmeyer, Graham
Romancik, Jason T.
Leslie, Lori A.
Merrill, Mwanasha H.
Crombie, Jennifer L.
Amoozgar, Behzad
Kahl, Brad S.
Bond, David A.
Maddocks, Kami J.
Okwali, Michelle
Seshan, Venkatraman
Salles, Gilles
Batlevi, Connie Lee
BLOOD, 2022, 140
[2] Tafasitamab and Lenalidomide in Relapsed/Refractory B-Cell Lymphoma: A Multicenter Retrospective Real-World-Study of Patients from Germany and Austria
Ruckdeschel, Anna
Sabrina, Koemm
Topp, Max S.
Greil, Richard
Melchardt, Thomas
Lenz, Georg
Kerkhoff, Andrea
Shumilov, Evgenii
Hess, Georg
Baumgaertner, Marta
Thurner, Lorenz
Kos, Igor Age
Mayer, Stephanie
Ayuk, Francis A.
Krause, Rolf
Herling, Marco
Vucinic, Vladan
Chapuy, Claudia
Illerhaus, Gerald
Knott, Markus
Viardot, Andreas
Grunenberg, Alexander
Dietrich, Sascha
Caille, Leandra
Tometten, Mareike C.
Rosa, Hyunyee
Scholz, Julia
Mueller, Fabian
Prochazka, Katharina
Chapuy, Bjoern
Boeckle, David
von Tresckow, Bastian
Schub, Natalie
Gelbrich, Goetz
Einsele, Hermann
Duell, Johannes
BLOOD, 2023, 142
[3] Real-World Outcomes of Adolescents and Young Adults with Diffuse Large B-Cell Lymphoma: A Multicenter Retrospective Cohort Study
Castro-Uriol, Denisse
Rios, Ligia
Enriquez-Vera, Daniel
Montoya, Jacqueline
Runciman, Thanya
Alarcon, Sandra
Zapata, Arturo
Hernandez, Eddy
Leon, Esmeralda
Malpica, Luis
Valcarcel, Bryan
JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY, 2024, 13 (02) : 323 - 330
[4] Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China
Wang, Shuo
Wang, Li
Hu, Jianda
Qian, Wenbin
Zhang, Xi
Hu, Yu
Zhu, Qi
Chen, Bobin
Wu, Depei
Chang, Chung-Chou H.
Xu, Pengpeng
Zheng, Xiaoyun
Wei, Juying
Liu, Yao
Cui, Guohui
Tang, Yong
Ma, Yan
Huang, Haiwen
Yi, Hongmei
Zhao, Weili
CANCER COMMUNICATIONS, 2021, 41 (03) : 229 - 239
[5] DIFFUSE LARGE B-CELL LYMPHOMA RESPONDS TO TAFASITAMAB PLUS LENALIDOMIDE
不详
CANCER DISCOVERY, 2020, 10 (08) : 1091 - 1091
[6] A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma
Liu Peng
Han Ying
Jiang Shi-Yu
He Xiao-Hui
Qin Yan
Gui Lin
Zhou Sheng-Yu
Zhou Li-Qiang
Yang Jian- Liang
Yang Sheng
Wen Ting-Yu
Shi Yuan-Kai
中华医学杂志英文版, 2019, 132 (15) : 1807 - 1814
[7] A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma
Liu, Peng
Han, Ying
Jiang, Shi-Yu
He, Xiao-Hui
Qin, Yan
Gui, Lin
Zhou, Sheng-Yu
Zhou, Li-Qiang
Yang, Jian- Liang
Yang, Sheng
Wen, Ting-Yu
Shi, Yuan-Kai
CHINESE MEDICAL JOURNAL, 2019, 132 (15) : 1807 - 1814
[8] Retrospective Analysis of Real-World Outcomes in Older Adult Patients With Diffuse Large B-Cell Lymphoma
Jobanputra, Kunal
Nayak, Lingaraj
Jain, Hasmukh
Bonda, V. N. Avinash
Thorat, Jayashree
Bagal, Bhausaheb
Sengar, Manju
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S372 - S373
[9] Real-world data for lenalidomide maintenance in responding patients of diffuse large B-cell lymphoma
Wang, Xiaoyan
Yu, Lu
Jiang, Xinlu
Ding, Kaiyang
CANCER MEDICINE, 2023, 12 (09): : 10553 - 10562
[10] Real-World Experience Using Tafasitamab Plus Lenalidomide and/or Loncastuximab Tesirine in a Predominately Hispanic Population with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Latiolais, Heidi
Horowitz, Justin
Michalek, Joel
Duque, Adolfo Enrique Diaz
BLOOD, 2024, 144 : 7780 - 7781

← 1 2 3 4 5 →